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Abstract
Objective
To characterize the neurologic phenotypes associated with COL4A1/2 mutations and to seek genotype–phenotype
correlation.
Methods
We analyzed clinical, EEG, and neuroimaging data of 44 new and 55 previously reported patients with COL4A1/COL4A2
mutations.
Results
Childhood-onset focal seizures, frequently complicated by status epilepticus and resistance to antiepileptic drugs, was the most
common phenotype. EEG typically showed focal epileptiform discharges in the context of other abnormalities, including generalized
sharpwaves or slowing. In 46.4% of new patients with focal seizures, porencephalic cysts on brainMRI colocalizedwith the area of the
focal epileptiform discharges. In patients with porencephalic cysts, brain MRI frequently also showed extensive white matter
abnormalities, consistent with the finding of diffuse cerebral disturbance on EEG. Notably, we also identified a subgroup of patients
with epilepsy as their main clinical feature, in which brain MRI showed nonspecific findings, in particular periventricular leu-
koencephalopathy and ventricular asymmetry. Analysis of 15 pedigrees suggested a worsening of the severity of clinical phenotype in
succeeding generations, particularly when maternally inherited. Mutations associated with epilepsy were spread across COL4A1 and
a clear genotype–phenotype correlation did not emerge.
Conclusion
COL4A1/COL4A2 mutations typically cause a severe neurologic condition and a broader spectrum of milder phenotypes, in
which epilepsy is the predominant feature. Early identification of patients carrying COL4A1/COL4A2 mutations may have
important clinical consequences, while for research efforts, omission from large-scale epilepsy sequencing studies of individuals
with abnormalities on brain MRI may generate misleading estimates of the genetic contribution to the epilepsies overall.
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COL4A1 and COL4A2 encode α1 and α2 chains of type IV
collagen, respectively, and share a common locus at 13q34.
One α2 and 2 α1 chains assemble into a heterotrimer of type
IV collagen, a structural component of basement membranes.
α-Chains are composed of 3 domains: the amino-terminal
region (7S), the carboxy-terminal region (NC1), which ini-
tiates heterotrimer assembly, and the collagenous part of the
molecule, the triple helix region (THR). The THR is com-
posed of amino acid triplet repeats (Gly-Xaa-Yaa), the first
being glycine (Gly) and the other 2 any amino acid.1 Most
pathogenic COL4A1/2 mutations are missense and lead to
substitution of a glycine with a different amino acid.2 In 2005,
semi-dominant Col4a1 mutations were demonstrated to in-
duce perinatal cerebral hemorrhages and predispose to por-
encephaly in an animal model, with COL4A1 mutations
segregating with human familial porencephaly.3 Sub-
sequently, it has been recognized that autosomal dominant
COL4A1 and COL4A2 mutations cause a broad spectrum of
cerebrovascular disease, whose onset occurs from fetal life
onward and whose severity may range from small-vessel dis-
ease to fatal intraparenchymal hemorrhage.4–8 While epilepsy
is known to be a clinical feature of porencephaly,3 the epilepsy
phenotypes associated with mutations in COL4A1 and CO-
L4A2 have not yet been detailed. We hypothesized that epi-
lepsy could be a manifestation of disease even in patients in
whom porencephaly is not evident and aimed to characterize
the phenotypes associated with COL4A1/COL4A2 muta-
tions, seeking genotype–phenotype correlation.
Methods
Standard protocol approvals, registrations,
and patient consents
This research was approved by the institutional ethics com-
mittees of the participating centers. Informed consent was
obtained from all participants, or from parents or legal
guardians of minors or individuals with intellectual disability.
A bespoke questionnaire was used to collect clinical and ge-
netic data.
Data were collected from published and new patients. Pub-
lished cases were sought using COL4A1 and COL4A2 as
keywords on PubMed/PubMed Gene and selected if they
provided sufficient clinical details: 31 articles were
reviewed.8–38
New patients were gathered through informal links and
contact with established consortia (EuroEPINOMICS RES
and Deciphering Developmental Disorders). They were in-
cluded if their variants were considered pathogenic, judged as
follows: nonsynonymous, splice-site altering, or truncating
changes; present less than 2 times in >120,000 controls in the
Genome Aggregation Database (gnomAD) browser and de
novo, inherited from an affected parent, or found in affected
siblings; or found in patients with MRI findings resembling
the previously known COL4A1/COL4A2 phenotype (e.g.,
with porencephaly). The following clinical variables were
assessed for all new patients: maternal complications during
pregnancy, antenatal and perinatal history, neuro-
psychological delay and cognitive disturbances, and seizure
history (age at seizure onset, seizure types, seizure frequency,
history of status epilepticus, antiepileptic drug history).
Seizures were classified according to the 2017 International
League Against Epilepsy (ILAE) classification and terminol-
ogy.39 Drug-resistant epilepsy was defined according to the
ILAE Consensus.40 Available EEG recordings and brain MRI
scans were evaluated. COL4A1 and COL4A2 mutations were
identified through various methods (table 1, doi.org/10.
5061/dryad.gj58t0v). The same data were sought from pub-
lished cases, though were not always available.
Statistical analysis
Data were tested for normal distribution. We applied the χ2
test to estimate the significance of the differences in perinatal
complications and Fisher exact test to assess the significance
of differences in prenatal evidence of brain pathology in 2
groups (maternal or paternal inheritance). We applied the
Wilcoxon matched-pairs signed-rank test to assess the dif-
ference in disease severity across generations in families with
established disease. Data were analyzed using Stata/IC 11.1
(StataCorp, College Station, TX).
Immunohistochemistry
Immunohistochemistry was performed from consented sur-
plus resected tissue from case 1 and compared with 3 control
cases (additional methods, doi.org/10.5061/dryad.gj58t0v).
Data availability
Data not published within the article are available in a public
repository (doi.org/10.5061/dryad.gj58t0v) and anonymized
data will be shared by request from any qualified investigator.
Results
General description of previously
published patients
Altogether, 123 patients, from 73 different families, and 69
different mutations (63 COL4A1 and 6 COL4A2) were
identified.8–38 Epilepsy was reported in 55 patients, all ana-
lyzed in this study, associated with 44 different mutations (42
Glossary
Gly = glycine; HELLP = hemolysis–elevated liver enzymes–low platelet; ILAE = International League Against Epilepsy;
MCD = malformations of cortical development; THR = triple helix region.
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for COL4A1 and 2 for COL4A2).8–29 Among published cases
with epilepsy, there were 12 of maternal origin, 11 of paternal
origin, 8 de novo mutations, and 24 with unknown in-
heritance. Genetic and clinical details are summarized in data
available from Dryad (table 2, doi.org/10.5061/dryad.
gj58t0v).
Demographic characteristics, mode of
inheritance, andprenatal andperinatal history
in new patients
Data are available from Dryad (table 3a/b, doi.org/10.5061/
dryad.gj58t0v). There were 46 new patients (24 male) in 9
countries: Germany (n = 14, 2 from the same family), United
Kingdom (n = 12), Italy (n = 10, 5 from the same family),
Denmark (n = 3), Australia (n = 2), United States (n = 2),
Estonia (n = 1), Japan (n = 1), and Portugal (n = 1). In this
cohort, 2 families were included (nos. 33a, 33b, 33c, 33d, and
33e and 23a and 23b), in which at least one participant (nos.
33b and 33d and 23a) had epilepsy. In 2 cases (nos. 26 and
28), epilepsy was not found after evaluation in specialized
centers, but these cases were retained in the current study
because they carried novel mutations and a compatible neu-
rologic phenotype, described below separately. Two cases
were excluded from further analysis due to uncertainty about
mutation pathogenicity.
In the final group of 44 new patients, mean age at last follow-
up was 9.7 years (SD ± 13.4): 7 patients were adults (mean
age 35.6 years; SD ± 15.4) and 37 individuals were children
(mean age 4.9 years; SD ± 3.7).
De novo mutations were identified in 24 patients; maternal
inheritance was found in 5 patients (including 2 sibling pairs),
paternal in 6 (2 of whom were siblings). In one family, the
parents tested negative, but both the proband (no. 26) and his
sister (not included in the study) carried the same mutation;
parental mosaicism is assumed but not proven. In 8 cases,
inheritance was unknown.
Natural delivery was reported in 28 patients. Delivery was
surgical in 15 patients, due to the following complications:
prenatal ventriculomegaly (nos. 4 and 10), severe intrauterine
growth retardation (no. 24), polyhydramnios (nos. 26 and
37), fetal arrhythmia (no. 2), intrauterine growth retardation
in the other fetus (not included in the cohort) (no. 27), fetal
microcephaly and mild renal pelvic dilation (no. 5), placenta
previa and intraventricular hemorrhage in utero detected by
fetal MRI (no. 17), mild maternal abdominal trauma 3 weeks
before due delivery date and subsequent failure to thrive and
pathologic cardiotocographic recording (no. 13),
hemolysis–elevated liver enzymes–low platelet (HELLP)
syndrome (no. 22), prolonged labor (no. 19/a), and sus-
pected hydrocephalus (no. 32); in 2, the reasons were un-
known (nos. 20 and 34). Prenatal evidence of vascular
cerebral insult was reported in 7 patients (nos. 4, 10, 17, 19/b,
29, 32, and 37). All patients with prenatal evidence of a cere-
bral vascular event or a prenatal complication requiring
surgical delivery developed severe intellectual disability and
abnormal neurologic signs.
Maternal complications during pregnancy included gesta-
tional diabetes (no. 38), placenta previa (no. 17), bleeding
during the first trimester treated with progesterone together
with detection of a single umbilical artery (no. 1), and HELLP
syndrome (no. 22). None of the mothers with pregnancy
complications carried themutation found in the affected child.
There were 6 late preterm births (nos. 13, 15, 18, 19/a, 20,
and 27). Head circumference at birth was known for 20
patients: 15 (nos. 1, 2, 4, 5, 9, 14, 19/a, 20, 21, 22, 24, 25, 29,
31, and 32) had microcephaly.
Seizure semiology, EEG features, and anatomo-
electroclinical correlations
Patients without epilepsy (nos. 23b, 26, 28, 33a, 33c, and 33e)
were excluded from this analysis.
Seizure types included focal-onset seizures, epileptic spasms,
and generalized tonic-clonic seizures without known focal
onset. Mean age at seizure onset was 15.4 (SD ± 26.4)
months. Focal-onset seizures, defined by seizure semiology
and interictal or ictal EEG findings, occurred in 28/38 patients
(73.7%), 10 of whom showed multifocal changes on ictal or
interictal EEG. Ictal EEG was available in 5 patients. Video-
EEG was not available. Among these 28, impairment of
awareness during seizures was described in 13 patients; evo-
lution to bilateral tonic-clonic seizures occurred in 11 patients.
Status epilepticus or prolonged seizures (lasting >5 minutes)
occurred in 15/38 patients (39.5%) (nos. 1, 2, 3, 9, 10, 13, 19/
a, 21, 23a, 29, 30, 31, 32, 34, and 36). Status epilepticus was
the presenting symptom in 4 patients (nos. 3, 19a, 23a, and
34). In 18/28 (64.3%) patients with focal seizures, EEG
showed diffuse abnormalities (spike-wave activity or gener-
alized slowing) and brain MRI revealed widespread white
matter alterations (periventricular leukoencephalopathy,
supratentorial white matter loss, and thinning of corpus cal-
losum). In 13/28 patients (46.4%), a porencephalic cyst or
a malformation of cortical development localized to the same
area as the identified seizure onset zone, with additional
widespread white matter abnormalities. In 15/28 (53.6%)
patients with focal seizures but no porencephaly, we found
diffuse abnormalities on brain MRI, including ventricular
enlargement and asymmetry or periventricular leukoence-
phalopathy and extensive white matter loss (nos. 3, 6, 7, 8, 9,
11, 15, 16, 19a, 19b, 27, 30, 33b, 33d, and 34).
Nine patients had epileptic spasms (nos. 12, 13, 17, 18, 20, 25,
32, 35, and 37). EEG was not available for patients 12 and 32.
In the other 7 patients, focal onset of spasms was demon-
strated on EEG and in 5 patients (nos. 17, 18, 20, 35, and 37)
an association was found between EEG localizing features and
a structural abnormality on brain MRI. One patient had
generalized tonic-clonic seizures only; EEG was not available
and it was not possible to exclude a focal onset (no. 29).
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Drug resistance was reported in 24/36 (66.6%); 8 patients
(22.2%) had a “good response” to treatment. No single drug
stood out for efficacy data (table 3a/b, doi.org/10.5061/
dryad.gj58t0v).
Three patients had surgical treatment for epilepsy. One pa-
tient (no. 27) with drug-resistant focal seizures underwent
corpus callosotomy at 6 years of age, with significant re-
duction in seizure frequency, with seizures currently every 6–8
weeks.41 No complications due to anesthetic or surgery were
reported. Patient 24, diagnosed with West syndrome at 6
months, underwent corpus callosotomy at 20 months.42 After
1 month of reduced seizure frequency, drug-resistant seizures
returned and psychomotor delay became evident. Functional
hemispherectomy was then performed, leading to seizure
freedom and subsequent improved head control and eye
contact. No surgical complications were reported. Patient 1
had surgery to remove a left temporo-occipital dysplasia at 21
months: the pathology is reported below. He remained
seizure-free at the latest follow-up, 1 year after surgery.
Of the 55 published patients with reported epilepsy, de-
scription of epilepsy phenotypes was provided in 16. Focal
seizures were reported in 11 patients: 5 had porencephaly on
MRI; 6 had periventricular leukoencephalopathy and irregular
enlargement of the lateral ventricles. Four patients with focal
epilepsy had EEG records reported, 2 showing a focal ab-
normality and generalized slowing and spike-wave activity,
with extensive hemispheric white matter loss and right-sided
porencephalic cyst on MRI. In one patient, EEG showed
a slow background and generalized spike-wave discharges,
with periventricular leukoencephalopathy and calcifications
on MRI. One patient had generalized tonic-clonic seizures
and a right-sided porencephalic cyst, 1 had epileptic spasms
with good response to vigabatrin and extensive periventricular
white matter changes, 1 had epileptic encephalopathy, and 2
had neonatal seizures.
In a subgroup of the new patients (5/38 [13%]) (nos. 3, 7, 8,
33/d, and 34) and 4/55 published cases12,17,21,28 (7%), epi-
lepsy was the presenting clinical problem.
Neuropsychological development and
neurologic examination in patients
with epilepsy
Intellectual impairment was found in 39/55 previously pub-
lished cases and in 36/38 new patients.
Neurologic examination showed a wide spectrum of motor
abnormalities: pyramidal signs and spasticity were reported in
21 new patients, dystonic features in 7, and hypotonia at birth
in 12. Four new patients (2 children [nos. 3 and 34] and 2
adults [nos. 33/d and 8]) had normal neurologic examination
at the mean age of 22.7 years at observation (SD ± 18.9 years):
notably, patients 8, 34, and 33/d had epilepsy onset after the
first year of life, at 11, 5, and 6 years, respectively. In published
patients, neurologic examination was abnormal in all but one.
Extra-CNS involvement in patients
with epilepsy
Ocular defects, reported in 16/55 published patients and 19/
38 new patients, were the most frequent extra-CNS signs and
comprised congenital cataract, retinal vessel tortuosity, and
anterior chamber dysgenesis. Increased serum creatine kinase
or muscle cramps were documented in 6 new and 7 published
patients. Kidney abnormalities (hematuria, hydronephrosis,
renal agenesis, and polycystic kidneys) were found in 3 pub-
lished and 3 new patients. Cardiac disease, reported in 3 new
patients and in 2 published patients, comprised mitral valve
prolapse, ventricular septal defect, tricuspid regurgitation, and
patent foramen ovale. The extra-CNS signs were already
present at the time of onset of epilepsy; the timing of onset of
the increased serum creatine kinase could not be established
from the histories and records available for review (tables 2
and 3a/b, doi.org/10.5061/dryad.gj58t0v).
Brain MRI findings in patients with epilepsy
A wide spectrum of abnormalities, summarized in figure 1,
was observed on brain MRI. In 29 cases, the brain MRI was
performed at epilepsy onset. Porencephaly (figure 1F) was
found in 31/55 (56%) published patients and in 15/38
(39.5%) new patients. All patients with porencephaly had
a complex syndromic presentation, with severe de-
velopmental delay, abnormalities on neurologic examination,
and early-onset, drug-resistant seizures. Malformations of
cortical development (MCD) (figure 1D), including schi-
zencephaly, polymicrogyria, focal cortical dysplasia, and
nodular heterotopia, were identified in 11 new (28.9%) and 7
(11%) published patients. Where present, MCD were always
associated with signs of white matter vascular insult
(i.e., periventricular leukoencephalopathy, ventricular dys-
morphisms, or white matter thinning).
Periventricular leukoencephalopathy (figure 1, B and C) was
reported in 11/55 (20%) published and 16/38 (42.1%) new
patients. Asymmetry of the lateral ventricles or basal ganglia
(figure 1, A and E) was reported in 9/55 (16.4%) published
and 22/38 (57.8%) new patients. Posterior fossa abnormali-
ties were reported in 6 new (15.8%) (nos. 2, 9, 17, 18, 29, and
38) and 7 (12.8%) published patients. In one new patient (no.
31), MRI angiography showed reduced development of left
medial and posterior cerebral arteries.
Longitudinal MRI data were available only for patients 1, 2, 5,
8, 9, 10, and 16: subsequent MRIs were performed within 3
years from the first one, except for patients 5 and 31, with 5
and 12 years follow-up, respectively. In all cases, consecutive
brain MRI findings were stable.
Phenotypes of patients 26 and 28
Patient 26 (COL4A1 p. G1169S), aged 17 at last follow-up,
had moderate learning difficulties and left hemiparesis. EEG
was normal and brain MRI, stable after 2 years, showed bi-
lateral fronto-parietal polymicrogyria and schizencephaly,
periventricular nodular heterotopia, and white matter loss.
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Patient 28 (COL4A1 p.G1207V), aged 16 years at last ob-
servation, had severe language impairment with dysarthria,
language automatism, and left spastic hemiparesis. Brain MRI
showed right fronto-parietal schizencephaly. No seizures were
reported. He had agenesis of the right kidney and a severe
ocular dysmorphism with bilateral ptosis, hemangioma of the
left superior eyelid, right cataract, and bilateral retinal atrophy.
Pathology
Pathology results are detailed in figure 2.
Figure 1 The spectrum of imaging abnormalities observed with COL4A1mutations
(A) Ventricular enlargement (arrows) and
dysmorphism (dotted arrow), thinning of
corpus callosum (*), white matter loss (pa-
tient 1). (B) Periventricular leukoencephal-
opathy (arrows) (patient 33/a). (C) Acute
germinal matrix hemorrhage on fetal brain
MRI (arrows) and consequent extensive leu-
koencephalopathy on postnatal brain MRI (*)
at 8 days of life (patient 33/c). (D) Malforma-
tions of cortical development: porencephaly
with schizencephalic cleft (dotted lines) and
polymicrogyria (arrows) (patient 17). (E) Dys-
morphism and asymmetry of basal ganglia
(patient 30). (F) Porencephaly (patient 17).
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Genetic findings
Seventy-three COL4A1 mutations, 42 from published and 31
from new patients, and 5 COL4A2 mutations, 2 from pub-
lished and 3 from new patients, all associated with epilepsy,
and the 2 novel mutations of cases 26 and 28 are shown in
figure 3, A and B. In the new cohort, 31 novel mutations were
identified. COL4A1 (NM_001845) mutations were spread
across the whole gene: 2 mutations were in the transcription
Figure 2 Neuropathologic evaluation of vascular pathology and blood–brain barrier integrity
(A–D) Immunostaining with smoothmuscle a-actin (SMA) shows no disruption or loss of vascular smoothmuscle cells. More numerous SMA-immunopositive
blood vessels inwhitematter were observed in the COL4A1 case (no. 1) (B) than in the control case (A). SMA expression in the COL4A1 casewas not restricted to
vascular arterioles (C) but was also observed in numerous vascular capillaries (D). (E–H) Evaluation of blood–brain barrier integrity using immunoglobulin G
(IgG) immunostaining. More marked IgG–immunopositive small vessel permeability was observed in the COL4A1 case (F) than in the control case (E). Strong
IgG immunolabeling was observed in processes with glial morphology, but not in neurons in the COL4A1 case (G, H). (I–P) Integrity of basal membrane. (I–L)
Laminin immunolabeling was present in arterioles and in capillaries with homogenous thickness in both the control (I) and the COL4A1 case (J–L). (M–P)
Expression of the COL4A1 protein. A regular pattern of immunolabelling in arterioles and capillaries presenting homogenous thickness was observed in the
control case (M) and the COL4A1 case (N–P). Scale bar (A, B, I–K, M–O) = 100 μm; (C, H) = 20 μm; (D, G, L, P) = 50 μm; (E, F) = 200 μm.
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initiation site, 68 in the THR, and 5 localized to the
C-terminal region. The 2 mutations localized in the initial part
of the gene (nos. 1 and 2) were associated with a severe
clinical phenotype, with onset of epilepsy at 3 months and
a history of status epilepticus. THR mutations comprised 9
splice-site and frameshift mutations, 1 substitution leading to
protein truncation, and 58 missense mutations leading to
glycine substitutions in Gly-Xaa-Yaa motifs. No obvious
correlation between the position of the mutation and the
severity of the associated phenotype was observed in the THR
region. The 5 mutations in the C-terminal domain were all
missense and were all associated with a severe syndromic
picture, except the variant p.C1551Y, found in patient 34, with
focal epilepsy and behavioral problems, normal neurologic
examination, nonspecific white matter lesions, and an arach-
noid cyst on MRI.
The COL4A1 p. G601S variant is newly described, identified
in 2 new patients (nos. 8 and 9). Patient 8 had developmental
delay, moderate cognitive impairment, autism, and normal
neurologic examination. Focal-onset drug-resistant seizures
started at 11 years of age. Brain MRI showed extensive
supratentorial white matter loss and abnormalities, originally
interpreted as perinatal infection. Patient 9 had onset of focal
drug-resistant seizures at age 10 months; neurologic exami-
nation showed microcephaly and hypotonia at birth. MRI
showed periventricular white matter loss, thinning of the
corpus callosum, and cerebellar atrophy.
The COL4A1 p.G720D variant was previously described in 2
families. In the first family,30 5 individuals had malformations
of the anterior chamber of the eye and cerebral vasculopathy
(one member had infantile-onset hemiparesis). No epilepsy
was reported in this family. In the second family,24 2 members
were affected. The proband had intraventricular hemorrhage
resulting in porencephaly and developed “generalized epi-
lepsy” in the first year of life. He also had optic coloboma and
cataract. His father had bilateral congenital cataracts, mi-
graine, and recurrent TIA.
We found 5 recurrent COL4A1 mutations: p.G601S,
p.G720D, p.G749S, p.G1044R, and p.G1239R. As detailed
below, they were usually associated with phenotypic
variability.
The COL4A1 p.G1044R variant was described as a de novo
mutation in a patient with low birthweight, congenital bi-
lateral cataracts, microcephaly, and porencephaly.19 Among
Figure 3 The distribution of mutations in the genes
The upper half of each figure depicts missense mutations, the lower half frameshift and splice-site mutations. (A) Distribution of COL4A1 mutations. (B)
Distribution of COL4A2 mutations.
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the new patients, we found a similar phenotype in a child who
died at 6 years of age (no. 24) and had bilateral porencephaly,
intractable epilepsy, profound global developmental delay,
microphthalmia, and congenital cataracts.
The COL4A1 p.G749S variant was described in an Italian
family11: 2 siblings had spastic quadriparesis and focal epi-
lepsy; their father had normal intellect and mild left hemi-
paresis. The same variant was found in a patient with prenatal
ultrasound evidence of massive brain parenchymal hemor-
rhage and neonatal seizures.27 His father, who had the mu-
tation, only had minor white matter abnormalities on
brain MRI.
The COL4A1 p.G1239R variant was first reported as a pater-
nally inherited mutation in a child with intracranial hemor-
rhage identified on prenatal screening and subsequent left
porencephaly and progressive hemolytic anemia.23 The father
had features of hereditary angiopathy with nephropathy,
aneurysms, and muscle cramps (HANAC) syndrome. In our
series of new cases, the same mutation was found de novo in
an affected 3-year-old girl. Surgical delivery was performed
because prenatal hydrocephalus was suspected. The child
developed microcephaly, severe cognitive impairment, and
drug-resistant epileptic spasms. Of note, her paternal grand-
mother died of a ruptured cerebral aneurysm (no other
clinical details were known).
The 5 COL4A2 (NM_001846) mutations were all missense
mutations and localized to the THR domain.
Analysis of pedigrees
The pedigree of an Italian family from the new group is
presented in figure 4. Five members carried mutation CO-
L4A1 p. G1369R and presented with very varied clinical
phenotypes.
Fifteen previously published kindreds were analyzed and are
illustrated in data available fromDryad (figure e-1, doi.org/10.
5061/dryad.gj58t0v). Severe phenotypes were preceded by
less typical clinical presentations of disease in the previous
generations. This generational gradient of disease severity was
associated with maternal inheritance in 11 families and pa-
ternal inheritance in 4.
To assess the severity of disease between different generations
in these families with established mutation, we built an ad-
ditive score including neurologic (epilepsy; intellectual im-
pairment; abnormal neurologic examination = 1 point each)
and neuroimaging (porencephaly; brain hemorrhage; diffuse
leukoencephalopathy; asymmetric ventricular system = 1
point each) data. The score was calculated for patients and
relatives in each family, and a significant difference in disease
severity was found when comparing across each generation
pair (Wilcoxon matched-pair signed-rank test, p < 0.001).
There was no significant difference between the groups of
maternal and paternal inheritance for the number of perinatal
complications (χ2, p = 0.07) or prenatal evidence of brain
pathology (Fisher exact test, p = 0.68). In the first 4 pedigrees
(figure e-1, a–d, doi.org/10.5061/dryad.gj58t0v), patients
with severe phenotypes, including porencephaly, succeed less
Figure 4MRI findings in a pedigree (cases 33a–33e) with COL4A1mutation (p.G1369R)
wt/m = wild-type/mutated.
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severe phenotypes having epilepsy as their main clinical fea-
ture. Of note, in the less severely affected patients, brain MRI
showed nonspecific findings (in particular periventricular
leukoencephalopathy and asymmetric enlargement of the
ventricular system) that would not have suggested the genetic
diagnosis until a more typical and severe phenotype appeared
in the family.
Discussion
In our series of new and published patients, the neurologic
patterns associated with COL4A1/COL4A2 mutations com-
prised a typical severe presentation and a spectrum of less
common phenotypes, in which epilepsy can be the pre-
dominant feature. In the present study, we retained the term
“porencephaly,” notwithstanding its lack of specificity, as it is
in common clinical usage. The typical severe phenotype was
characterized by porencephalic cysts on brain MRI, and
clinically defined by severe developmental delay, intellectual
and behavioral difficulties, microcephaly, and motor abnor-
malities on neurologic examination, with involvement of both
pyramidal and extrapyramidal systems.
We identified a subgroup of new and published patients in
which epilepsy was the main feature leading to medical at-
tention, associated with mild to moderate intellectual or be-
havioral difficulties, while neurologic examination showed
slight and insidiously developing motor abnormalities. Two
adult patients with epilepsy had normal neurologic examina-
tion: patient 33/d was diagnosed after a severe phenotype of
disease appeared in the family. Patient 8 was diagnosed 25
years after epilepsy onset after specialist review. Milder pre-
sentations are likely underdiagnosed, due to limited awareness
of the full spectrum of neurologic presentations, such that
clinicians (in particular those seeing adults) may suspect
COL4A1/2 etiology only in the most severe cases. The di-
agnosis in milder cases with new-onset epilepsy is challenging
because of the nonspecific brain MRI features
(i.e., asymmetric ventricular enlargement, diffuse periven-
tricular leukoencephalopathy, white matter thinning), whose
causation is frequently attributed to traumatic or hypoxic-
ischemic birth injury and intrauterine infections. For instance,
new patient 8 was initially diagnosed with epilepsy secondary
to unidentified perinatal infection. A similar misdiagnosis was
previously described.22 Notably, the involvement of other
organs (especially eyes, kidneys, andmuscles) was found to be
already present at the time of onset of epilepsy and can pro-
vide a diagnostic clue.
We also observed a generational gradient of disease severity,
especially with maternal inheritance. COL4A1/2mutations in
the fetus induce susceptibility to intrauterine environment
stressors that increase the risk of intraventricular hemor-
rhage.7 Since COL4A1/COL4A2 are among the maternal
susceptibility genes for preeclampsia,43 we hypothesized that
a mutation expressed in the maternal uterus may further
increase the risk of prenatal brain complications and, conse-
quently, the severity of disease. Our analysis did not show
a significant difference in prenatal and perinatal complications
between maternally and paternally inherited cases. However,
we suggest this hypothesis as one explanation, for testing in
future studies as the low numbers and potential selection
biases may have limited the conclusions of the present study.
The pedigree in figure 4 also highlights that asymptomatic
carriers (nos. 33/c and 33/e) can precede severe phenotypes.
This observation suggests a reduced penetrance of COL4A1/
COL4A2 mutations that may partly contribute to the gener-
ational gradient of disease severity.
COL4A1/COL4A2 mutation-related seizures typically had
focal onset, also in cases with epileptic spasms. EEG record-
ings showed focal or multifocal epileptiform discharges and
generalized, frequently asymmetric, abnormalities (general-
ized spike-waves or diffuse slowing). Focal epileptiform dis-
charges were related to a specific lesion (in particular
porencephalic cysts, schizencephaly, or polymicrogyria) in
46.4% of patients, while in the remaining patients, less specific
EEG abnormalities were described, without a clear correlation
with a focal lesion. This complex anatomo-electroclinical
picture suggests different pathogenic associations. The most
typical is through predisposition to hemorrhagic and ischemic
insults, as demonstrated by mouse models.3,4 MCD were also
associated with Col4a1 mutations, as a result of defects of
cortical lamination.44 Here, we found a notably high preva-
lence (28.9% of new cases) of polymicrogyria, schizencephaly,
or focal cortical dysplasia.
De novo mutations seemed more common in the newly
identified patients. One possible explanation of this discrep-
ancy is that growing evidence of de novo variants in epilepsy
causation has led to an increasing search for such variants, and
a slight move away from familial studies. However, the
numbers in this study are modest overall and for some pub-
lished cases data on inheritance were unavailable; thus, we
cannot draw secure conclusions on this aspect.
An increased awareness of COL4A1/2-related epilepsy phe-
notypes has clinical and research implications. One is for
follow-up. COL4A1/COL4A2 mutations are established
monogenic causes of stroke and can present for the first time
in adult life with features of cerebral small-vessel disease, in-
cluding subcortical hemorrhage and ischemic stroke, with
lacunar infarcts, leukoaraiosis, and cerebral microbleeds on
MRI,6 suggesting a dynamic evolution of COL4A1/2 leu-
koencephalopathy. Although our subset of longitudinal MRI
data did not demonstrate progressive increase in the burden
of cerebrovascular disease, important limitations (young age,
low numbers, short follow-up) hamper definitive statements.
Although data on the risk from COL4A1/2 mutations for
future intracerebral hemorrhage or ischemic stroke remain
limited, these mutations might increase the intracranial
hemorrhagic risk in anticoagulated patients: one patient car-
rying COL4A1 mutation p.G562E died at age 40 after
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a spontaneous cerebral hemorrhage while on oral
anticoagulation.25,26 The intracranial bleeding risk during IV
thrombolysis in patients carrying COL4A1/COL4A2 muta-
tions also needs consideration. The presence of cerebral
microbleeds on brain MRI might help to identify those with
COL4A1/COL4A2 mutations at highest risk of intracranial
hemorrhage prior to anticoagulation or thrombolysis.45,46
Epilepsy surgery, including both functional surgical procedures
(like corpus callosotomy) and focal resections, was performed
in 3 patients. To our knowledge, patient 1 is the first with
a known COL4A1 mutation to have undergone a resection of
MCD, resulting in complete seizure control. Although we are
aware of only 3 patients with this genetic condition treated
surgically, notably the outcomes have been successful, in terms
of both safety and effectiveness. There is rising interest in the
role of genetic diagnostics during presurgical evaluation.47 The
genetic epilepsies are heterogeneous and for some (e.g., focal
cortical dysplasia due to mutations in MTOR pathway genes),
surgery may be appropriate, while for other genetic conditions
surgerymay not be effective.47 It is therefore desirable that each
causation is considered gene by gene in a multidisciplinary
team, with, wherever possible, decisions based on un-
derstanding of the underlying mechanisms of disease. The
evidence so far, although limited, suggests that surgery may be
a valid option for drug-resistant COL4A1/2-associated epi-
lepsy. The presurgical evaluation should consider other organ
involvement (which may contribute to an increased perioper-
ative risk). Broadening the spectrum of clinical phenotypes
associated with COL4A1/COL4A2 mutations may help our
understanding of the genetic architecture of the epilepsies.
Many large-scale genetic research efforts tend to exclude people
with structural changes on MRI, including cysts and periven-
tricular leukoencephalopathy. The epilepsy phenotypes asso-
ciated with COL4A1/COL4A2mutations suggest that this may
not be the most comprehensive strategy to determine the full
effect of genetic variation in the causation and biology of the
epilepsies, or to best apply genetically driven precision medi-
cine approaches.48
There are certain phenotypic pointers to considering CO-
L4A1/2mutations in individual patients, with implications for
individual patient management and for our understanding of
epilepsy genetics.
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